Novo Nordisk Surges On Wegovy Win, Eyes Bullish Rebound Near 52-Week Lows
1. NVO shares surged on FDA's accelerated approval for Wegovy. 2. The approval could stabilize sales amid competition for GLP-1 treatments. 3. NVO is trading above key moving averages, indicating bullish momentum. 4. Analysts suggest the stock may lead to renewed investor interest. 5. Lowered sales growth forecast contrasts with potential Wegovy-driven rebound.